Coronavirus Update: Synairgen Tests First Inhaled Candidate, No New China Cases
While Survey Shows Looming Crisis In Trial Recruitment
More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.
You may also be interested in...
Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.
Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start
Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.